AKT1 and breast carcinoma: Combined treatment with the same doses of these agents resulted in a significant decrease in phospho-Akt, PDK-1, and PI3K levels as compared to MDA-MB-231 breast cancer cells in the vehicle-treated control group (Figure 10(b)).